Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

Who May Be Eligible (Plain English)

Who May Qualify: - Subjects must have a diagnosis of COPD - at their clinical baseline on the day of imaging - must be clinically stable in order to participate in the study. - COPD subjects will be categorized according to the GOLD - Current/Former SmokerSubjects - must have a smoking history ≥ 10 pack years Who Should NOT Join This Trial: - Dx of asthma - Continuous oxygen use at home - Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging - FEV1 percent predicted less than 25% - Pregnancy or lactation - Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning - Subjects with any implanted device that cannot be verified as MRI compliant will be excluded - Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches - History of congenital cardiac disease, chronic renal failure, or cirrhosis - Inability to understand simple instructions or to hold still for approximately 10 seconds - History of respiratory infection within 2 weeks prior to the MR scan - History of MI, stroke and/or poorly controlled hypertension. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Subjects must have a diagnosis of COPD * at their clinical baseline on the day of imaging * must be clinically stable in order to participate in the study. * COPD subjects will be categorized according to the GOLD * Current/Former SmokerSubjects * must have a smoking history ≥ 10 pack years Exclusion Criteria: * Dx of asthma * Continuous oxygen use at home * Blood oxygen saturation of 92% less than as measured by pulse oximetry on the day of imaging * FEV1 percent predicted less than 25% * Pregnancy or lactation * Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning * Subjects with any implanted device that cannot be verified as MRI compliant will be excluded * Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches * History of congenital cardiac disease, chronic renal failure, or cirrhosis * Inability to understand simple instructions or to hold still for approximately 10 seconds * History of respiratory infection within 2 weeks prior to the MR scan * History of MI, stroke and/or poorly controlled hypertension.

Treatments Being Tested

DRUG

Hyperpolarized Xenon-129 MRI (Experimental)

MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)

DRUG

Radioactive Xenon-133 scintigraphy (Active Comparator)

Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)

Locations (1)

University of Virginia Health System
Charlottesville, Virginia, United States